CytomX Therapeutics (NASDAQ:CTMX) Receives Neutral Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of CytomX Therapeutics (NASDAQ:CTMX) in a research report report published on Monday morning,Benzinga reports. HC Wainwright also issued estimates for CytomX Therapeutics’ Q4 2024 earnings at ($0.01) EPS, FY2024 earnings at $0.14 EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.12) EPS.

CytomX Therapeutics Stock Performance

Shares of NASDAQ:CTMX opened at $1.00 on Monday. The firm has a 50 day simple moving average of $1.13 and a 200 day simple moving average of $1.46. CytomX Therapeutics has a 52 week low of $0.98 and a 52 week high of $5.85. The company has a market cap of $78.26 million, a PE ratio of 5.94 and a beta of 1.06.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.23. The business had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $18.92 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same quarter last year, the firm posted $0.04 earnings per share. On average, equities analysts predict that CytomX Therapeutics will post -0.13 earnings per share for the current year.

Institutional Trading of CytomX Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new position in CytomX Therapeutics in the 1st quarter valued at approximately $57,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of CytomX Therapeutics by 10.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock worth $331,000 after acquiring an additional 26,373 shares during the last quarter. US Bancorp DE acquired a new position in shares of CytomX Therapeutics in the third quarter worth $40,000. Acadian Asset Management LLC raised its holdings in shares of CytomX Therapeutics by 1.4% during the second quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company’s stock worth $3,324,000 after acquiring an additional 37,739 shares in the last quarter. Finally, Cubist Systematic Strategies LLC boosted its position in CytomX Therapeutics by 96.6% during the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 40,309 shares during the last quarter. 67.77% of the stock is owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.